Nowell J. Solish

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Development of a Core Outcome Domain Set for Facial Aging.

Development of a Core Outcome Domain Set for Facial Aging.

Journal: JAMA dermatology

Published: June 17, 2026

Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial.

Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial.

Journal: Aesthetic surgery journal

Published: April 17, 2025

Canada HARMONY Study: Improvements in Patient Satisfaction With Facial Appearance and Psychological Impact of Combined Aesthetic Treatment.

Canada HARMONY Study: Improvements in Patient Satisfaction With Facial Appearance and Psychological Impact of Combined Aesthetic Treatment.

Journal: Aesthetic surgery journal. Open forum

Published: February 20, 2025

Management and Prevention of Neuromodulator Complications.

Management and Prevention of Neuromodulator Complications.

Journal: Journal of drugs in dermatology : JDD

Published: January 06, 2025

NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials.

NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials.

Journal: Aesthetic surgery journal

Published: November 26, 2024

Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines.

Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines.

Journal: Aesthetic surgery journal

Published: June 24, 2024

Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Randomized Phase 2 Dose-Ranging Study.

Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Randomized Phase 2 Dose-Ranging Study.

Journal: Plastic and reconstructive surgery

Published: April 19, 2024

Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion.

Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion.

Journal: Journal of drugs in dermatology : JDD

Published: April 02, 2024

Optimized Aesthetic Outcomes When Treating Glabellar Lines with Botulinum Toxin Type A: GLO 3 + 2: A Precise Technique Based on Anatomy.

Optimized Aesthetic Outcomes When Treating Glabellar Lines with Botulinum Toxin Type A: GLO 3 + 2: A Precise Technique Based on Anatomy.

Journal: Plastic and reconstructive surgery. Global open

Published: July 14, 2023

Bridging the Gap: Sustained Treatment Effect of Glabellar Lines With Twice-A-Year Treatment With DaxibotulinumtoxinA.

Bridging the Gap: Sustained Treatment Effect of Glabellar Lines With Twice-A-Year Treatment With DaxibotulinumtoxinA.

Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Published: June 29, 2023

Optimizing Outcomes When Treating Glabellar Lines.

Optimizing Outcomes When Treating Glabellar Lines.

Journal: Aesthetic surgery journal

Published: May 22, 2023

Decades of beauty: Achieving aesthetic goals throughout the lifespan.

Decades of beauty: Achieving aesthetic goals throughout the lifespan.

Journal: Journal of cosmetic dermatology

Published: April 07, 2023

Showing 1-12 of 58

Last Updated: 09/26/2026